Sarcoma: History and Discovery
The word sarcoma is one of the oldest in the language of medicine, but the disease it names today is one of the most modern of medical ideas. For nearly two thousand years “sarcoma” meant little more than a fleshy lump. Only when nineteenth-century pathologists learned to look at tumors through the microscope did the word acquire its present, precise meaning: a malignant cancer that begins not in the body’s linings and glands, but in its scaffolding — the bone, muscle, fat, cartilage, and blood vessels that hold us together. This is the story of how an ancient Greek word for “a fleshy growth” became the name of a rare, diverse, and scientifically pivotal family of cancers.
Table of Contents
- An Ancient Word: Sarx, Flesh, and the Greek Roots
- Galen and the Ancient “Fleshy Tumor”
- The Microscope and a New Definition: Müller and Virchow
- Sarcoma versus Carcinoma: Connective Tissue Cancer
- Peyton Rous, a Chicken Tumor, and the Birth of Cancer Virology
- Naming the Subtypes: Osteosarcoma, Ewing, and Kaposi
- A Rare and Diverse Family of Cancers
- From Surgery to Targeted Therapy
- Research Papers and References
- Connections
An Ancient Word: Sarx, Flesh, and the Greek Roots
The word sarcoma is built from two Greek pieces. The first is sarx (genitive sarkos), meaning flesh — the same root that gives us words such as sarcophagus (literally “flesh-eater,” from the limestone coffins the ancients believed consumed the body) and the modern medical term sarcopenia (age-related loss of muscle flesh). The second piece is the suffix -oma, which in Greek and in later medical Latin came to mean a swelling, growth, or tumor. Joined together, sarkōma meant simply a fleshy excrescence or fleshy substance — a lump that looked and felt like flesh.
It is worth pausing on how literal and descriptive this naming was. Ancient physicians had no microscope, no concept of the cell, and no theory of how cancers begin. They classified growths the only way they could: by how they looked and felt to the eye and hand. A “sarcoma” was a growth with the soft, fleshy character of muscle or other meaty tissue, as distinct from a hard, stony lump or a watery cyst. The name recorded an appearance, not a cause. This is the crucial distinction to keep in mind throughout this history: the ancient word and the modern disease share a name and a root, but the precise, tissue-of-origin meaning the word carries today is a nineteenth-century achievement layered on top of a classical label.
The suffix -oma went on to become one of the workhorses of medical vocabulary, generating carcinoma, lymphoma, melanoma, glioma, and hundreds of other terms. In most of these the -oma signals a tumor of a particular tissue or cell type. Sarcoma was, in a sense, one of the patterns from which that whole naming convention grew — flesh plus growth, an idea simple enough to survive from antiquity into the twenty-first-century oncology clinic.
Galen and the Ancient “Fleshy Tumor”
The term enters the historical record in the writings of Greek and Greco-Roman physicians, and it is most strongly associated with Galen of Pergamon (c. 129 – c. 216 CE), the towering medical authority whose works dominated Western and Islamic medicine for well over a thousand years. Etymological scholarship traces the Latinized form sarcoma, “fleshy substance,” directly to Galen, and Galen and his predecessors used the term broadly for soft, fleshy tumors and outgrowths — not for a single, defined disease as we would understand it. In the humoral medicine of the day, such growths were explained as accumulations or corruptions of the body’s fluids, not as diseases of a specific tissue or cell.
For centuries afterward, “sarcoma” remained a loosely descriptive word in the surgical and medical literature, applied to a wide range of fleshy masses. The English word is recorded from the 1650s in the sense of a “fleshy excrescence,” carried into English through medical Latin. As late as the early nineteenth century the meaning was still shifting: the English surgeon John Abernethy, writing around 1804, is credited with using “sarcoma” in the narrower sense of a more or less malignant tumor of the soft, fleshy tissues — an important step toward the modern meaning, but one that still predated any real understanding of what such tumors were made of.
So at the threshold of the modern era, the situation was this: medicine had inherited a venerable word, sarcoma, for fleshy tumors, and a vague sense that some of these growths were dangerous. What it lacked entirely was a way to look inside a tumor and ask what kind of tissue it came from. That capacity arrived with the microscope, and it would transform “sarcoma” from a description of texture into a statement about the deepest origin of a cancer.
The Microscope and a New Definition: Müller and Virchow
The decisive shift came in the first half of the nineteenth century, when pathologists began applying the newly developed achromatic microscope and the emerging cell theory to the study of tumors. The pivotal figure was the German physiologist and pathologist Johannes Müller (1801–1858). In 1838 Müller published a landmark monograph — rendered in English as On the Nature and Structural Characteristics of Cancer, and of Those Morbid Growths Which May Be Confounded with It (German: Über den feineren Bau und die Formen der krankhaften Geschwülste) — in which he examined tumors under the microscope and showed that different growths are built from different kinds of microscopic tissue. Müller demonstrated that tumors are composed of cells, and he distinguished various tumor types by their cellular structure, including cartilaginous, fatty, and “cysto-sarcomatous” growths. The work is widely regarded as a founding document of pathological histology — the study of diseased tissue under the microscope — and it established the principle that the structure of a tumor, not merely its outward feel, defines what it is.
Müller’s student Rudolf Virchow (1821–1902) carried this revolution to its conclusion. In his 1858 lectures, published as Die Cellularpathologie (Cellular Pathology), Virchow argued that all disease, including cancer, must be understood at the level of the cell, and he made famous the principle omnis cellula e cellula — every cell arises from a pre-existing cell. In his three-volume work on tumors, Die krankhaften Geschwülste (1863–1867), Virchow systematically classified growths by their tissue of origin. Virchow had shown that bone and connective tissue are themselves made of cells, and he held that many tumors arise from these connective tissues. With his work, the idea that a cancer could be classified by the normal tissue it most resembled — and presumably came from — moved to the center of pathology.
It is important to mark this as the true birth of the modern concept. The ancient word survived, but its meaning was rebuilt from the cell up. “Sarcoma” ceased to mean “a lump that feels fleshy” and began to mean something far more specific: a malignant tumor whose cells resemble, and arise from, the body’s connective and supporting tissues. That redefinition is what made it possible, in the decades that followed, to give precise names to the individual sarcomas.
Sarcoma versus Carcinoma: Connective Tissue Cancer
The most important consequence of the nineteenth-century revolution was a clean division of the malignant tumors into two great families, based on the kind of tissue they come from. The human body’s tissues can be sorted, in simplified terms, into two broad groups. Epithelial tissues are the linings and coverings — the skin’s surface, the lining of the gut, lungs, ducts, and bladder, and the cells of glands such as the breast and prostate. Mesenchymal (or connective) tissues are the body’s structural framework — bone, cartilage, muscle, fat, fibrous tissue, and blood vessels — the materials that give the body shape, support, and movement.
From this division comes the defining distinction of sarcoma. A carcinoma is a malignant cancer arising from epithelial tissue; carcinomas are by far the most common human cancers and include most breast, lung, colon, prostate, and skin cancers. A sarcoma, by contrast, is a malignant cancer arising from mesenchymal / connective tissue. A cancer of bone-forming cells is an osteosarcoma; of fat, a liposarcoma; of smooth muscle, a leiomyosarcoma; of skeletal muscle, a rhabdomyosarcoma; of cartilage, a chondrosarcoma; of blood-vessel lining, an angiosarcoma. The suffix records the malignancy and the Greek root sarx records the fleshy, mesenchymal origin, while the prefix names the specific tissue. This is why the same word that once meant merely “a fleshy growth” is now a precise statement about a tumor’s deepest cellular ancestry.
This sarcoma-versus-carcinoma framework, worked out as cellular pathology matured in the nineteenth century, remains the first and most fundamental branch point in how oncologists classify solid tumors today. It explains why sarcomas behave so differently from the common carcinomas — they spread by different routes, respond to different drugs, and demand different surgery — and it is the reason sarcomas are managed by specialized teams rather than alongside the far more numerous epithelial cancers.
Peyton Rous, a Chicken Tumor, and the Birth of Cancer Virology
One sarcoma, in a barnyard bird, changed the entire course of cancer science. In 1911, the American physician-scientist Peyton Rous (1879–1970), working at the Rockefeller Institute in New York, was studying a spindle-cell tumor — a sarcoma — that had appeared in the breast of a Plymouth Rock hen. Rous ground up the tumor, passed the material through a fine filter fine enough to remove all cells and even bacteria, and injected the resulting cell-free filtrate into healthy chickens. Remarkably, the healthy birds developed the same sarcoma. Because nothing living larger than a virus could have passed the filter, Rous had shown that a virus could cause cancer. The agent became known as the Rous sarcoma virus (RSV).
The claim was so far ahead of its time that it was met with skepticism for decades, and Rous himself largely set the work aside for years. Vindication came slowly but completely. Rous was finally awarded the Nobel Prize in Physiology or Medicine in 1966 — 55 years after the discovery, the longest gap between a discovery and its Nobel recognition in the history of the prize. By then his chicken sarcoma had become the single most studied tumor virus in biology and the foundation of modern cancer virology.
The deepest payoff came in the 1970s. Researchers found that the Rous sarcoma virus carries a specific cancer-causing gene, named src (pronounced “sarc,” after sarcoma) — the first oncogene ever identified. The crucial follow-on discovery was that a closely related gene already exists, in normal and harmless form, in the cells of healthy animals and humans; the virus had essentially captured and corrupted a normal cellular gene. This insight — that cancer genes are altered versions of the body’s own genes — reshaped the entire understanding of how cancer arises and earned its own Nobel Prize in 1989. It is one of the great ironies and triumphs of the field that this whole edifice of molecular cancer biology, including the very concept of the oncogene, rests on the study of a single sarcoma in a hen.
Naming the Subtypes: Osteosarcoma, Ewing, and Kaposi
As pathology matured, individual sarcomas were carved out and named, several of them carrying the names of the physicians who first described them. Osteosarcoma — literally “bone-flesh-tumor,” the most common primary cancer of bone — takes a purely descriptive name from its tissue of origin and was already well recognized to clinicians by the early twentieth century, typically in adolescents and treated, in that era, by amputation.
Kaposi sarcoma bears the name of the Hungarian-born Viennese dermatologist Moritz Kaposi (1837–1902), who in 1872 published the first description of the condition under the title “Idiopathic multiple pigmented sarcoma of the skin” (Idiopathisches multiples Pigmentsarkom der Haut) in the Archiv für Dermatologie und Syphilis. Kaposi described several patients — classically reported as five men — with aggressive pigmented skin lesions, one of whom died with tumors found in the lungs and gut at autopsy. The disease remained a medical rarity for more than a century until it surged into prominence in the early 1980s as one of the defining opportunistic cancers of the AIDS epidemic; it is now known to be driven by a herpesvirus (human herpesvirus 8) in the setting of immune suppression.
Ewing sarcoma is named for the American pathologist James Ewing (1866–1943), a founding figure of American oncology. In 1921, Ewing reported to the New York Pathological Society several cases of a bone tumor he called diffuse endothelioma of bone — describing, among others, a 14-year-old girl with a tumor of the radius that had first been mistaken for an osteosarcoma. Ewing’s key contribution was recognizing this as a distinct entity, separate from the already-known osteosarcoma and from lymphoma. The eponym “Ewing’s sarcoma” was introduced a few years later, in 1928 (by Oberling), to settle a confusion of competing names. Today Ewing sarcoma is understood as an aggressive small-round-cell tumor of bone and soft tissue, most common in children and young adults, and defined at the molecular level by a characteristic chromosomal translocation.
A Rare and Diverse Family of Cancers
One of the most important things to understand about sarcoma is that it is not a single disease but a large and varied family. Modern classifications recognize more than fifty distinct subtypes, conventionally divided into two big groups: the bone sarcomas (osteosarcoma, chondrosarcoma, Ewing sarcoma, and others) and the far more numerous soft-tissue sarcomas (liposarcoma, leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, gastrointestinal stromal tumor, and many more). Each subtype has its own typical age range, its own favored location in the body, its own behavior, and increasingly its own molecular signature.
Sarcomas are also genuinely rare. Taken together, all sarcomas account for only a small percentage of adult cancers — on the order of about 1% — though they make up a notably larger share of childhood cancers, where bone sarcomas and rhabdomyosarcoma are important diagnoses. Their rarity has real consequences: sarcomas are easy to mistake for benign lumps or other tumors, they are frequently misdiagnosed at first, and the evidence base for any one subtype is thinner than for the common carcinomas. For these reasons, expert guidelines strongly favor managing sarcomas at specialized sarcoma centers, where pathologists and surgeons see enough cases to recognize the patterns. Because sarcomas can arise anywhere connective tissue exists — which is to say nearly anywhere in the body — this diversity is intrinsic to the disease rather than an inconvenience of classification.
From Surgery to Targeted Therapy
For most of its history, the treatment of sarcoma meant the knife, and often a drastic one. Because sarcomas grow within bone and muscle and were so often recognized late, the classical answer to a bone sarcoma such as osteosarcoma was amputation of the affected limb. Surgery — complete removal of the tumor with a margin of healthy tissue — remains the cornerstone of treatment for most localized sarcomas to this day, but its character has changed enormously. Over the second half of the twentieth century, the addition of chemotherapy and radiation therapy around the time of surgery transformed outcomes for several sarcomas and, crucially, made limb-sparing surgery possible for many patients who would once have lost an arm or a leg.
The most celebrated modern advance, however, came from understanding a sarcoma at the molecular level. The gastrointestinal stromal tumor (GIST) — the most common sarcoma of the digestive tract — was found to be driven, in most cases, by an abnormally active growth-signal receptor called KIT (or, in some tumors, a related receptor, PDGFRA). The drug imatinib (marketed as Gleevec / Glivec), originally developed against a different molecular target in chronic myeloid leukemia, was found to block KIT as well. The U.S. Food and Drug Administration approved imatinib for advanced GIST on February 1, 2002, and it is widely described as the first effective molecularly targeted therapy for a solid tumor — a drug aimed at the specific molecular fault driving the cancer rather than at all dividing cells. Its success turned a sarcoma that had been almost untreatable when it could not be removed surgically into a frequently controllable disease, and it became a textbook proof of principle for targeted cancer therapy as a whole.
The arc of this history is striking. A word for “fleshy growth” that Galen used eighteen centuries ago became, through the microscope, a precise category of connective-tissue cancer; a sarcoma in a chicken opened the molecular age of oncology; and a sarcoma of the gut, the GIST, became one of the first cancers ever defeated by a drug designed to hit its exact molecular cause. The science continues: newer targeted agents and, increasingly, genomic profiling of individual sarcoma subtypes are extending this same logic across the more than fifty members of the sarcoma family. For the practical, present-day clinical picture — symptoms, diagnosis, staging, and the full range of current treatments — see the main Sarcoma page.
Research Papers and References
The references below combine peer-reviewed historical and review articles with curated PubMed topic-search links into the literature on the history, classification, and biology of sarcoma. Where a stable identifier is available it is given as a DOI or PMID link; the remaining entries are topic searches that open at PubMed (National Library of Medicine) in a new tab. The historical primary works named in the article — Galen’s writings, Johannes Müller’s 1838 monograph, Rudolf Virchow’s Cellular Pathology (1858) and Die krankhaften Geschwülste (1863–1867), Moritz Kaposi’s 1872 paper, and James Ewing’s 1921 report — are cited in the text as historical sources.
- Wright JR Jr. The First Tumor Pathologist: Johannes Müller (1801–1858) and the “Geschwülste” (1838) and the histogenesis of cancer. Annals of Clinical & Laboratory Science. 2004;34(3):355–356. — PubMed: Müller, the first tumor pathologist
- Müller J. (Classics in oncology, historical reprint) On the nature and structural characteristics of cancer: general observations on the minute structure of morbid growths. CA: A Cancer Journal for Clinicians. 1973;23(5):307–312. — doi:10.3322/canjclin.23.5.307
- Virchow R. Cellular Pathology as Based upon Physiological and Pathological Histology (1858) and tumor pathology — historical analysis. — PubMed: Virchow, cellular pathology and tumors
- Vogt PK. Retroviral oncogenes: a historical primer. Nature Reviews Cancer. 2012;12(9):639–648. — doi:10.1038/nrc3320
- Martin GS. The road from Rous sarcoma virus to precision medicine. Journal of Experimental Medicine. 2021;218(4):e20201754. — doi:10.1084/jem.20201754
- Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. Journal of Experimental Medicine. 2011;208(12):2351–2355. — doi:10.1084/jem.20112160
- Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 1976;260(5547):170–173. — doi:10.1038/260170a0
- Cripe TP. Ewing sarcoma: an eponym window to history. Sarcoma. 2011;2011:457532. — doi:10.1155/2011/457532
- Ewing J. (Classics in oncology, historical reprint) Diffuse endothelioma of bone. Proceedings of the New York Pathological Society. 1921. — PubMed: Ewing, diffuse endothelioma of bone (1921)
- Sternberg SS. Moritz Kaposi: idiopathic pigmented sarcoma of the skin. American Journal of Dermatopathology. 1995. — PubMed: Kaposi, idiopathic pigmented sarcoma of the skin
- Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clinical Cancer Research. 2002;8(10):3034–3038. — PubMed: imatinib approval summary for GIST
- History and classification of soft-tissue and bone sarcomas (WHO classification, subtypes). — PubMed: sarcoma classification and history
- Etymology and historical evolution of the term “sarcoma.” — PubMed: history and terminology of sarcoma
- Epidemiology of sarcoma — rarity, subtypes, and specialized care. — PubMed: sarcoma epidemiology and rarity
External Authoritative Resources
- National Cancer Institute (NCI) — Soft Tissue Sarcoma
- The Nobel Prize — Peyton Rous, 1966 (tumour-inducing viruses)
- PubMed — Research on the history and pathology of sarcoma